Following the FDA's decision, Mike Brown, Phibro’s vice-president of mineral nutrition and aqua in North America, stated: “We are excited to further support the US aquaculture industry’s efforts to reach its production and sustainability goals by bringing to market a proven, cost-effective, florfenicol antimicrobial product. We share our customers’ commitment to improving productivity through good health management practices. By bringing Paqflor to market Phibro is giving producers more health management options.”
The antibiotic is a 50 percent (500 g / kg) florfenicol premix. In salmonids it’s typically used the control of mortality due to furunculosis associated with Aeromonas salmonicida and coldwater disease associated with Flavobacterium psychrophilum. In catfish it’s used for the control of mortality due to columnaris disease associated with Flavobacterium columnare and enteric septicaemia associated with Edwardsiella ictaluri.
Meanwhile for warmwater finfish, such as tilapia, it can be used to control streptococcal septicaemia, as associated with Streptococcus iniae. It is administered at a dose rate of 10 – 15 mg/kg body weight per day of florfenicol for 10 days.
Todd Armstrong, Phibro’s president in North America added: “Having a new aquaculture product in the US allows Phibro to continue our mission of providing safe and effective solutions for our customers’ unique health challenges.”
*Paqflor is a registered trademark
